Physician profile
Eric J Bell
NPI 1891217204
$905.39
in general payments reported to CMS, 2019-2025
21 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $81.25 · 2022: $27.20 · 2023: $431 · 2024: $194 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $137.21 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $117.27 | 2024-2025 | Evenity |
| Pfizer INC. | $67.78 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.56 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $52.82 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $50.87 | 2023-2024 | Breztri, Airsupra |
| Medtronic, INC. | $48.67 | 2023 | Linq II |
| Cerapedics INC. | $45.53 | 2021 | |
| Exact Sciences Corporation | $38.60 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $37.71 | 2023-2025 | Ozempic, Rybelsus |
| Hologic Sales and Service, LLC | $35.72 | 2021 | |
| Abbvie INC. | $33.93 | 2025 | |
| Neurocrine Biosciences, INC. | $28.16 | 2023 | Ingrezza, Ongentys |
| Sanofi-Aventis U.S. LLC | $27.97 | 2025 | |
| Astellas Pharma US INC | $26.66 | 2023 | Veozah |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $22.96 | 2023 | Watchman Access System |
| E.R. Squibb & Sons, L.L.C. | $20.21 | 2025 | Eliquis |
| Lilly USA, LLC | $16.30 | 2023 | Jardiance, Emgality |
| Otsuka America Pharmaceutical, INC. | $16.13 | 2023 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $14.06 | 2025 | |
| Corcept Therapeutics | $13.27 | 2023 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.